EFFICACYOF SHUNTHYADI ASCHYOTANA AND TRIPHALADI COMPOUND IN THE MANAGEMENT OF SHUSHKAKSHIPAKA (DRY EYE)

Efficacy of Shunthyadi Aschyotana and Triphaladi compound in the management of Shushkakshipaka (dry eye) - An open labelled randomized comparative clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023469

Enrollment

Registered

2020-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H049- Disorder of lacrimal system, unspecified

Interventions

Intervention1: Shunthyadi Aschyotana and Triphaladi compound: Shunthyadi Aschyotana(external eye drops 1 drop in both eyes 4 times a day) and Triphaladi compound(orally 500mg tablet thrice daily with

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with signs and symptoms of Shushkaakshipaka (Dry eye disease) described asperAyurveda and Modern science will be included in the study.

Exclusion criteria

Exclusion criteria: Dry Eye due to any local cause e.g. Allergicconjunctivitis ,Xerosis etc. Dry Eye due to systemic disease like Sjogrenâ??s Syndrome. Patients on Steroids, Oral Contraceptive pills,Estrogen replacement therapy or any othermedication such as Antispasmodic drugs like Atropine that may adversely affectthe outcome of the study. Persistent contact lens users.

Design outcomes

Primary

Measure	Time frame
Relief in signs and symptoms of ShushkakshipakaTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Improvement in quality of life and social wellbeing of patientsTimepoint: within 1 year from the trial	—

Countries

India

Contacts

Public ContactDr D B Vaghela

Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University Jamnagar

drvaghela@rediffmail.com9825407899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026